In a significant stride for battlefield medicine and emergency trauma care, California-based medical technology firm Abram Scientific has been awarded a substantial contract by the Defense Advanced Research Projects Agency (DARPA). The agreement, worth up to $8.3 million, marks a pivotal moment for the company’s flagship point-of-care (POC) diagnostic platform, "CoagCare." By bridging the gap between slow, centralized laboratory testing and the immediate, life-saving needs of frontline military units and civilian first responders, Abram Scientific is positioning itself at the forefront of blood coagulation diagnostics.
This influx of capital arrives at a crucial juncture for the company, following a successful $10.75 million Series A financing round concluded in February 2026. With a bolstered balance sheet and a clear mandate from the Department of Defense (DoD), Abram is now aggressively pursuing US Food and Drug Administration (FDA) clearance, aiming to redefine how coagulation status is managed in resource-limited environments.
The Core Innovation: Solving the “Golden Hour” Problem
Traditional coagulation diagnostics, such as thromboelastography, are staples of modern hospital settings but often fail to meet the requirements of emergency scenarios. These legacy systems typically require between 30 and 60 minutes to deliver results—a lifetime when a patient is suffering from acute, trauma-induced hemorrhaging.
Abram’s CoagCare platform is engineered to dismantle these temporal barriers. Designed as a portable, point-of-care diagnostic, CoagCare provides an accurate assessment and characterization of a patient’s blood coagulation status in under 10 minutes. By delivering actionable clinical data rapidly, the device allows medical personnel to make informed decisions regarding blood product administration, potentially preventing the fatal cascade of ischemia-induced dysfunction.
The platform is designed to be as effective in a ruggedized military field hospital as it is in a suburban emergency department. By miniaturizing laboratory-grade technology, Abram aims to ensure that "actionable intelligence" regarding blood clotting is available exactly where it is needed most: at the patient’s side.
Chronology of Development and Financial Milestones
The path to the current DARPA award is the result of a deliberate, multi-year strategy focused on technological refinement and strategic capital raising.
- October 2025: Abram Scientific secures an initial $2 million tranche from DARPA. This foundational funding was specifically earmarked for the miniaturization of the CoagCare system, ensuring the device could meet the stringent weight and size requirements of field deployment.
- February 2026: The company successfully closes a $10.75 million Series A financing round. This private-sector capital provided the operational runway necessary to scale manufacturing processes and prepare for the rigorous regulatory scrutiny of the FDA.
- Late 2026: Following the successful demonstration of the miniaturized prototype, DARPA awards the follow-on contract of up to $8.3 million. This funding is intended to transition the technology from the laboratory to mass production and field readiness.
- Current Status: The company is currently engaged in the final stages of pre-market preparations, with the primary objective of securing FDA clearance to bring CoagCare to the broader civilian market while simultaneously fulfilling its military-grade requirements.
The RAPIID Program: A Strategic Mandate
The funding awarded by DARPA falls under the agency’s Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program. RAPIID is a specialized research initiative tasked with developing groundbreaking technologies that can prevent organ failure and death in trauma patients who cannot immediately reach a traditional surgical facility.
The DARPA mandate for Abram Scientific is twofold:
- Regulatory Acceleration: To provide the resources necessary to finalize the FDA filing process, ensuring the device meets the safety and efficacy standards required for domestic medical use.
- Clinical Optimization: Beyond mere diagnostics, the funding is tasked with optimizing the CoagCare system to support the administration of "shelf-stable blood analogue components." This is a critical development for military logistics, where the ability to store and utilize synthetic or shelf-stable blood substitutes in extreme environments could mean the difference between life and death for soldiers injured in remote conflict zones.
Additionally, the funds will facilitate the establishment of robust manufacturing capabilities for both the CoagCare meter and its proprietary disposable test cards. This vertical integration is essential to ensure a reliable supply chain for the military and to maintain cost-efficiency for civilian healthcare providers.
Official Perspectives: The Vision for Life-Saving Diagnostics
Abhishek Ramkumar, the founder and CEO of Abram Scientific, has consistently emphasized the human cost of current technological limitations in trauma care.
"Rapid access to actionable coagulation information can be critical for saving lives in trauma care, when every minute matters," Ramkumar stated following the announcement. "This DARPA award recognizes the importance of bringing laboratory-quality coagulation information closer to the patient and supports our efforts to develop a platform that can ultimately serve both military and civilian medicine."
By framing the technology as a dual-use asset, Ramkumar underscores the broader mission of Abram Scientific: to democratize access to high-end diagnostic care. Whether in a conflict zone, an air ambulance, or a rural hospital lacking specialized laboratory facilities, the platform is designed to eliminate the information vacuum that often leads to improper or delayed blood transfusion strategies.
Implications for Military and Civilian Medicine
The successful deployment of the CoagCare platform holds profound implications for the future of emergency medicine.
Transforming Combat Casualty Care
Military medicine is defined by the "Golden Hour"—the period following traumatic injury during which prompt medical treatment has the highest likelihood of preventing death. By providing a portable, rapid diagnostic, the military can shift from "blind" blood product administration to precision resuscitation. This not only saves lives but also preserves precious, life-saving blood supplies that are difficult to transport and maintain in forward-operating bases.
Impact on Civilian Emergency Response
For the civilian sector, the integration of CoagCare into emergency medical services (EMS) and rural hospitals could significantly improve survival rates for trauma victims, such as those involved in high-speed motor vehicle accidents or industrial injuries. Many rural hospitals lack the personnel and infrastructure to run complex coagulation panels. A device that offers lab-quality results within 10 minutes could serve as a force multiplier for these smaller facilities, enabling them to stabilize patients more effectively before transferring them to level-one trauma centers.
Economic and Logistical Efficiency
From a logistical perspective, the development of a system that works in tandem with shelf-stable blood analogues represents a paradigm shift. If blood analogues can be administered effectively based on real-time diagnostic data, the logistical burden of "cold chain" logistics (maintaining refrigerated blood products) is drastically reduced. This would fundamentally change how global health organizations and military forces handle blood storage and management in the field.
Future Outlook: Navigating the FDA Path
While the DARPA contract provides a substantial runway, the road ahead for Abram Scientific remains challenging. The FDA clearance process is notoriously rigorous, requiring extensive clinical validation and evidence that the device performs reliably under diverse conditions.
However, the company’s recent track record suggests a high degree of confidence. By successfully navigating the technical hurdles of miniaturization in 2025 and securing significant private and government investment in 2026, Abram has proven that it can deliver on its milestones. The next 18 to 24 months will be critical, as the company shifts its focus from research and development to regulatory submission and commercial scaling.
As the lines between military research and civilian clinical application continue to blur, Abram Scientific’s work stands as a testament to the power of targeted, government-backed innovation. By tackling the specific, high-stakes problem of blood coagulation, the company is not just building a diagnostic tool; it is building a vital component of the future trauma care infrastructure—one that ensures that when the time for action comes, the right data is available, and the right decisions are made, without delay.
About the Author
